ATP Inks Michelob Ultra Deal In U.S. Rockies' Monfort Explains Payroll Bump Molson Coors Selling Stake In Rockies Athlete Charities In Wisconsin Examined Chris Kermode Set To Become Next ATP Leader Crandon Park Tennis Center Approved For Expansion Djokovic, Nadal Want ATP World Finals Moved Chris Kermode A Leading Candidate To Head ATP Monfort Will Not Alter Rockies' Front Office California Bill Limits Athlete Workers' Comp Claims
FDA TO LAY OFF ANDRO; DENVER WRITER CHASTISED FOR SNOOPING
Published August 28, 1998
The FDA "said it has no reason to step up scrutiny" of androstenedione after all the attention the product has received this week, according to Kristin Reed of BLOOMBERG NEWS. FDA spokesperson Ruth Welch: "The FDA is not aware that this product used in the marketplace presents a hazard to the public health" (BLOOMBERG NEWS, 8/28). Meanwhile, the ATP Tour banned androstenedione and will inform players of the move before the U.S. Open on Monday. The ruling "adds to the ban instituted" by the ITF (N.Y. TIMES, 8/28). CAUGHT SNOOPING: The BBWAA has "suspended" Denver Post columnist Mark Kiszla until the end of the regular season after he was "seen picking up" a bottle of Andro-6 from Rockies LF Dante Bichette's locker during batting practice Wednesday, "a time when the clubhouse generally is closed to all media." Kiszla later addressed the team in a clubhouse meeting on Thursday. The Rockies also revoked Kiszla's credentials (Tony Jackson, ROCKY MOUNTAIN NEWS, 8/28).